First report of linezolid-resistant cfr-positive methicillin-resistant Staphylococcus aureus in humans in Portugal

Linezolid and vancomycin are the most reliable therapeutic agents to treat complicated soft tissue infections caused by multidrug-resistant methicillin-resistant Staphylococcus aureus (MRSA) strains. However, despite the fact that the prevalence of linezolid-resistant MRSA strains (LR-MRSA) remains overall low, in the past few years resistance to linezolid has been reported among human patients worldwide, imposing a public-health concern, in particular when associated with a mobile gene such as cfr [1]. The aim of this study was to identify LR-MRSA isolates recovered from infected diabetic foot ulcers and to characterise their antimicrobial resistance profiles and genetic lineage. (...)

Descrição

Letter to the Editor

Palavras-chave

Linezolid LR-MRSA cfr Portugal Resistência aos Antimicrobianos

URI

http://hdl.handle.net/10400.18/6505

Citação

J Glob Antimicrob Resist . 2019 Jun;17:323-325. doi: 10.1016/j.jgar.2019.05.017. Epub 2019 May 22

Editora

Elsevier/ on Behalf of International Society of Chemotherapy for Infection and Cancer

DOI

10.1016/j.jgar.2019.05.017

Coleções

DDI - Artigos em revistas internacionais

Métricas Alternativas

Ver registo completo